Neuberger Berman Group LLC Cuts Position in Sanofi $SNY

Neuberger Berman Group LLC decreased its position in shares of Sanofi (NASDAQ:SNY) by 14.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,878 shares of the company’s stock after selling 5,338 shares during the period. Neuberger Berman Group LLC’s holdings in Sanofi were worth $1,540,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Level Four Advisory Services LLC purchased a new stake in Sanofi in the second quarter worth approximately $404,000. Grantham Mayo Van Otterloo & Co. LLC boosted its position in Sanofi by 19.2% during the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 42,673 shares of the company’s stock valued at $2,062,000 after buying an additional 6,865 shares during the period. Elevation Point Wealth Partners LLC grew its holdings in Sanofi by 14.9% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 31,315 shares of the company’s stock worth $1,513,000 after acquiring an additional 4,059 shares during the last quarter. FourThought Financial Partners LLC increased its position in shares of Sanofi by 28.7% in the second quarter. FourThought Financial Partners LLC now owns 9,572 shares of the company’s stock valued at $462,000 after acquiring an additional 2,136 shares during the period. Finally, Aviso Financial Inc. boosted its holdings in shares of Sanofi by 4.3% during the second quarter. Aviso Financial Inc. now owns 45,035 shares of the company’s stock worth $2,176,000 after purchasing an additional 1,838 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.4%

Sanofi stock opened at $49.85 on Friday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock has a fifty day moving average of $49.56 and a 200 day moving average of $49.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. The stock has a market cap of $122.41 billion, a PE ratio of 11.67, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the prior year, the company earned $2.25 earnings per share. The firm’s revenue was down 7.5% on a year-over-year basis. As a group, sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Weiss Ratings restated a “hold (c+)” rating on shares of Sanofi in a research report on Monday. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $56.00 to $58.00 in a report on Monday, September 8th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.